- Home
- SVRA vs ETON Comparison
SVRA vs ETON Comparison
Compare SVRA & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | ETON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SVRA | ETON |
|---|---|---|
| Price | $5.28 | $40.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $7.33 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 1.6M | 538.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | $430.87 | $47.23 |
| P/E Ratio | ★ N/A | $816.00 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $2.92 | $14.27 |
| 52 Week High | $7.01 | $50.18 |
Technical Indicators
Market Signals| Indicator | SVRA | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 45.96 |
| Support Level | $4.77 | $15.77 |
| Resistance Level | $5.43 | $50.18 |
| Average True Range (ATR) | 0.28 | 2.64 |
| MACD | -0.00 | -0.94 |
| Stochastic Oscillator | 11.73 | 3.29 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.